INS19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology
Alternative Names: INS19 CAR-T cells; INS19CAR-TLatest Information Update: 06 Mar 2024
Price :
$50 *
At a glance
- Originator Beijing Immunochina Medical Science and Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 25 Jan 2024 Preclinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma in China (Parenteral) before January 2024
- 15 Jan 2024 Beijing Immunochina Medical Science & Technology plans a phase I trial for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second line therapy or greater) in January 2024 (NCT06209671)